111 related articles for article (PubMed ID: 15467441)
1. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
[TBL] [Abstract][Full Text] [Related]
2. Irofulven: resurgence for alkylating therapy in cancer?
Dent P; Grant S
Cancer Biol Ther; 2004 Nov; 3(11):1143-4. PubMed ID: 15640616
[No Abstract] [Full Text] [Related]
3. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
[TBL] [Abstract][Full Text] [Related]
4. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.
Liang H; Salinas RA; Leal BZ; Kosakowska-Cholody T; Michejda CJ; Waters SJ; Herman TS; Woynarowski JM; Woynarowska BA
Mol Cancer Ther; 2004 Nov; 3(11):1385-96. PubMed ID: 15542777
[TBL] [Abstract][Full Text] [Related]
5. Irofulven induces replication-dependent CHK2 activation related to p53 status.
Wang Y; Wiltshire T; Senft J; Reed E; Wang W
Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
[TBL] [Abstract][Full Text] [Related]
6. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
[TBL] [Abstract][Full Text] [Related]
7. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
[TBL] [Abstract][Full Text] [Related]
8. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
[TBL] [Abstract][Full Text] [Related]
9. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
11. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic trial of irofulven.
Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
17. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.
Woynarowska BAHigdon AL; Muñoz RM; Bushong P; Waters SJ
Invest New Drugs; 2001; 19(4):283-91. PubMed ID: 11561687
[TBL] [Abstract][Full Text] [Related]
18. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
[TBL] [Abstract][Full Text] [Related]
19. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
Dick RA; Yu X; Kensler TW
Clin Cancer Res; 2004 Feb; 10(4):1492-9. PubMed ID: 14977853
[TBL] [Abstract][Full Text] [Related]
20. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
Clodi K; Kliche KO; Zhao S; Weidner D; Schenk T; Consoli U; Jiang S; Snell V; Andreeff M
Cytometry; 2000 May; 40(1):19-25. PubMed ID: 10754513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
